Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Neoplasms 7Carcinoma, Non-Small-Cell Lung 6Heart Diseases 3Vascular Diseases 2Small Cell Lung Carcinoma 2Leukemia, Myeloid, Acute 2Cardiovascular Diseases 2Cardiotoxicity 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Recurrence 1Rectal Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Cancer Resectable 1Ovarian Carcinosarcoma 1Noonan Syndrome 5 1Neoplasms, Second Primary 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Metabolic Diseases 1Liver Neoplasms 1Leukemia, Monocytic, Acute 1Leukemia, Lymphoid 1Immune-related Adverse Event 1Hematologic Neoplasms 1Heart Failure 1Esophageal Neoplasms 1Early Hormone Receptor-positive Breast Cancer 1Drug-Related Side Effects and Adverse Reactions 1Colorectal Neoplasms 1

Interventions

pembrolizumab 163Carboplatin 146Paclitaxel 125Cyclophosphamide 94130-nm albumin-bound paclitaxel 66Capecitabine 64Gemcitabine 54Doxorubicin 50Albumin-Bound Paclitaxel 45Taxes 42atezolizumab 41Cisplatin 39sacituzumab govitecan 34Nivolumab 34olaparib 32Epirubicin 32Specimen Handling 28Docetaxel 28eribulin 27Bevacizumab 26durvalumab 25Drug Therapy 25Biopsy 24camrelizumab 23Magnetic Resonance Spectroscopy 22toripalimab 19Radiotherapy 17spartalizumab 16Everolimus 15veliparib 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × Antineoplastic Agents × Clear all
NCT03799679 2019-01-10

Albumin-Bound Paclitaxel Followed by Epirubicin in Combination With Cyclophosphamide in Triple Negative Breast Cancer

Fudan University

Phase 4 Unknown
60 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡